Monoclonal Antibodies in Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Monoclonal Antibodies in Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry, 4(5): 411-414.

Author(s): Barbara Gatto.

Affiliation: Department of Pharmaceutical Sciences, University of Padova, via Marzolo 5, 35131 Padova.


The recent approval of cetuximab and bevacizumab by FDA for the treatment of metastatic colorectal cancer witnesses the investments of biotech companies in the development of monoclonal antibodies (Mabs) as cancer therapeutics. Several analyses point to the growth of the market for these drugs, and forecast an even higher expansion of sales following completion of several clinical trials, both of approved Mabs tested for other cancers, and of new Mabs aimed at different tumor antigens. Not unsurprisingly, the latest additions to the number of therapeutic Mabs belong to the classes of chimeric and humanized antibodies. A great effort has been made in the last years to overcome the intrinsic limitations of the technology used to produce monoclonal antibodies. The knowledge accumulated in the search of newer ways of production of recombinant therapeutic proteins is reflected by the number of fully human Mabs in the pipeline. Moreover, a thorough understanding of the cellular and molecular events underlying the activity of cancer-aimed antibodies allows the optimisation of these drugs for the treatment of high incidence solid tumors.


monoclonal-antibodies, mabs, biotechnology, cancer-therapy, conjugated-mabs, chimeric-mabs, humanized-mabs, fully-human-mabs.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 5
First Page: 411
Last Page: 414
Page Count: 4
DOI: 10.2174/1568011043352713
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science